Gabriela Bezerra Sorato

Dr. Gabriela Bezerra Sorato

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
ARAndré Luiz Schuh Teixeira da Rosa
André Luiz Schuh Teixeira da Rosa
MCMarina Ribeiro Barreto da Costa
Marina Ribeiro Barreto da Costa
GSGabriela Bezerra Sorato
Gabriela Bezerra Sorato
FMFelipe de Moura Manjabosco
Felipe de Moura Manjabosco
ÉBÉrica Bonganhi de Bem
Érica Bonganhi de Bem
AGAna Soledade Graeff-Martins
Ana Soledade Graeff-Martins
Background: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition emerging in early childhood, characterized by core features such as sociocommunicative deficits and repetitive, rigid behaviors, interests, and activities. In addition to these, disruptive behaviors (DB), including aggression, self-injury, and severe tantrums, are frequently observed in pediatric patients with ASD. The atypical antipsychotics risperidone and aripiprazole, currently the only Food and Drug Administration–approved treatments for severe DB in patients with ASD, often encounter therapeutic failure or intolerance. Given this, exploring pharmacological alternatives for more effective management of DB associated with ASD is essential. Clozapine, noted for its unique antiaggressive effects in schizophrenia and in various treatment-resistant neuropsychiatric disorders, independent from its antipsychotic efficacy, remains underexplored in youths with ASD facing severe and persistent DB. Objective: This study aimed to evaluate the efficacy, tolerability, and safety of clozapine for treatment-resistant DB in youths with ASD. Methods: This is a prospective, single-center, noncontrolled, open-label trial. After a cross-titration phase, 31 patients with ASD aged 10-17 years and with treatment-resistant DB received a flexible dosage regimen of clozapine (up to 600 mg/day) for 12 weeks. Standardized instruments were applied before, during, and after the treatment, and rigorous clinical monitoring was performed weekly. The primary outcome was assessed using the Irritability Subscale of the Aberrant Behavior Checklist. Other efficacy measures include the Clinical Global Impression Severity and Improvement, the Swanson, Nolan, and Pelham questionnaire-IV, the Childhood Autism Rating Scale, and the Vineland Adaptive Behavior Scale. Safety and tolerability measures comprised adverse events, vital signs, electrocardiography, laboratory tests, physical measurements, and extrapyramidal symptoms with the Simpsons-Angus Scale. Statistical analysis will include chi-square tests with Monte Carlo simulation for categorical variables, paired t tests or Wilcoxon tests for continuous variables, and multivariate linear mixed models to evaluate the primary outcome, adjusting for confounders. Results: Recruitment commenced in February 2023. Data collection was concluded by April 2024, with analysis ongoing. This article presents the protocol of the initially planned study to provide a detailed methodological description. The results of this trial will be published in a future paper. Conclusions: The urgent need for effective pharmacological therapies in mitigating treatment-resistant DB in pediatric patients with ASD underscores the importance of this research. Our study represents the first open-label trial to explore the anti-aggressive effects of clozapine in this specific demographic, marking a pioneering step in clinical investigation. Adopting a pragmatic approach, this trial protocol aims to mirror real-world clinical settings, thereby enhancing the applicability and relevance of our findings. The preliminary nature of future results from this research has the potential to pave the way for more robust studies and emphasize the need for continued innovation in ASD treatment. Trial Registration: Brazilian Clinical Trials Registry RBR-54j3726; https://ensaiosclinicos.gov.br/rg/RBR-54j3726 International Registered Report Identifier (IRRID): DERR1-10.2196/58031

1 January 2024 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
LDLucas Dellazari
Lucas Dellazari
ÉBÉrica Bonganhi de Bem
Érica Bonganhi de Bem
AFArthur Bezerra Falcão
Arthur Bezerra Falcão
FMFelipe de Moura Manjabosco
Felipe de Moura Manjabosco
GSGabriela Bezerra Sorato
Gabriela Bezerra Sorato
ACArthur Caye
Arthur Caye
The Brazilian Journal of Psychiatry is the official publication of Brazilian Psychiatric Association (Associação Brasileira de Psiquiatria - ABP)

23 July 2026 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
ARAndré Luiz Schuh Teixeira da Rosa
André Luiz Schuh Teixeira da Rosa
GSGabriela Bezerra Sorato
Gabriela Bezerra Sorato
FMFelipe de Moura Manjabosco
Felipe de Moura Manjabosco
LDLucas Dellazari
Lucas Dellazari
ÉBÉrica Bonganhi de Bem
Érica Bonganhi de Bem
AGAna Soledade Graeff-Martins
Ana Soledade Graeff-Martins
Objective: Severe disruptive behaviors in youth with autism spectrum disorder (ASD) frequently persist despite conventional treatments, contributing to functional impairment. Although clozapine has antiaggressive properties, evidence guiding its use in treatment-resistant cases in autistic youth remains predominantly observational and retrospective. This study aimed to evaluate systematically and prospectively the effectiveness and safety of clozapine for treatment-resistant disruptive behaviors (TR-DB) in youth with ASD under routine conditions. Methods: This single-arm, open-label trial enrolled participants aged 10–17 with ASD. Inclusion required TR-DB after ≥2 antipsychotic trials and a Clinical Global Impression–Severity score ≥5. Following flexible titration, clozapine was maintained for 12 weeks. The primary outcome was change on the caregiver-rated Aberrant Behavior Checklist–Irritability (ABC-I). Secondary measures included global improvement, autism symptom severity, adaptive behavior, and caregiver quality of life. Response was defined as ≥30% ABC-I reduction plus a CGI–Improvement (CGI-I) of 1 to 2; remission required ≥80% ABC-I reduction and a CGI-I of 1. Results: Thirty-one participants initiated clozapine treatment (mean age 13.4 years; 90.3% male), and 28 completed the trial. ABC-I scores decreased from 32.0 ± 7.7 to 7.4 ± 5.1 (Cohen’s d z −2.5; p < 0.001). Overall, 83.9% responded, and 38.7% remitted. Global severity improved from 6.1 ± 0.6 to 3.8 ± 1.6 ( p < 0.001). Significant improvements were observed in daily living skills, caregiver quality of life, and reduced polypharmacy. Adverse drug reactions were mostly mild-to-moderate; however, metabolic changes comprised significant weight gain and triglyceride elevation (both p < 0.05). Serious events included seizures ( n = 4) and pneumonia ( n = 1). Conclusions: Clozapine was associated with robust, rapid TR-DB reductions and high retention in autistic youth. However, safety risks mandate rigorous monitoring. Controlled trials are needed to confirm efficacy and refine the benefit–risk profile.

3 March 2024 in JMIR Preprints
Verified
Preprint
Open access
ARAndré Luiz Schuh Teixeira da Rosa
André Luiz Schuh Teixeira da Rosa
MCMarina Ribeiro Barreto da Costa
Marina Ribeiro Barreto da Costa
GSGabriela Bezerra Sorato
Gabriela Bezerra Sorato
FMFelipe de Moura Manjabosco
Felipe de Moura Manjabosco
ÉBÉrica Bonganhi de Bem
Érica Bonganhi de Bem
AGAna Soledade Graeff-Martins
Ana Soledade Graeff-Martins
BACKGROUND Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition emerging in early childhood, characterized by core features such as sociocommunicative deficits and repetitive, rigid behaviors, interests, and activities. In addition to these, disruptive behaviors (DB), including aggression, self-injury, and severe tantrums, are frequently observed in pediatric patients with ASD. The atypical antipsychotics risperidone and aripiprazole, currently the only Food and Drug Administration–approved treatments for severe DB in patients with ASD, often encounter therapeutic failure or intolerance. Given this, exploring pharmacological alternatives for more effective management of DB associated with ASD is essential. Clozapine, noted for its unique antiaggressive effects in schizophrenia and in various treatment-resistant neuropsychiatric disorders, independent from its antipsychotic efficacy, remains underexplored in youths with ASD facing severe and persistent DB. OBJECTIVE This study aimed to evaluate the efficacy, tolerability, and safety of clozapine for treatment-resistant DB in youths with ASD. METHODS This is a prospective, single-center, noncontrolled, open-label trial. After a cross-titration phase, 31 patients with ASD aged 10-17 years and with treatment-resistant DB received a flexible dosage regimen of clozapine (up to 600 mg/day) for 12 weeks. Standardized instruments were applied before, during, and after the treatment, and rigorous clinical monitoring was performed weekly. The primary outcome was assessed using the Irritability Subscale of the Aberrant Behavior Checklist. Other efficacy measures include the Clinical Global Impression Severity and Improvement, the Swanson, Nolan, and Pelham questionnaire-IV, the Childhood Autism Rating Scale, and the Vineland Adaptive Behavior Scale. Safety and tolerability measures comprised adverse events, vital signs, electrocardiography, laboratory tests, physical measurements, and extrapyramidal symptoms with the Simpsons-Angus Scale. Statistical analysis will include chi-square tests with Monte Carlo simulation for categorical variables, paired t tests or Wilcoxon tests for continuous variables, and multivariate linear mixed models to evaluate the primary outcome, adjusting for confounders. RESULTS Recruitment commenced in February 2023. Data collection was concluded by April 2024, with analysis ongoing. This article presents the protocol of the initially planned study to provide a detailed methodological description. The results of this trial will be published in a future paper. CONCLUSIONS The urgent need for effective pharmacological therapies in mitigating treatment-resistant DB in pediatric patients with ASD underscores the importance of this research. Our study represents the first open-label trial to explore the anti-aggressive effects of clozapine in this specific demographic, marking a pioneering step in clinical investigation. Adopting a pragmatic approach, this trial protocol aims to mirror real-world clinical settings, thereby enhancing the applicability and relevance of our findings. The preliminary nature of future results from this research has the potential to pave the way for more robust studies and emphasize the need for continued innovation in ASD treatment. CLINICALTRIAL Brazilian Clinical Trials Registry RBR-54j3726; https://ensaiosclinicos.gov.br/rg/RBR-54j3726 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/58031

25 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
GSGabriela Bezerra Sorato
Gabriela Bezerra Sorato
JLJessica Vargas Lopes
Jessica Vargas Lopes
APAna Carolina Gomes Petry
Ana Carolina Gomes Petry
DGDaniel Pasini Gonçalves
Daniel Pasini Gonçalves
IFIsabela Alicia Fink
Isabela Alicia Fink
AVAna Carolina Sgarioni Viapiana
Ana Carolina Sgarioni Viapiana
Background: Alzheimer's disease (AD) is the leading cause of dementia among the elderly. Although advances in understanding its pathophysiology have led to the development of therapies, current pharmacological treatments mainly focus on symptom management and do not significantly alter disease progression. Recently, anti‐amyloid monoclonal antibodies (mAbs) have emerged as promising therapies, directly targeting beta‐amyloid plaques. However, the efficacy and safety of these therapies remain debated. This study reviews the current literature on the use of mAbs in AD. Method: A narrative literature review was conducted using articles published since 2019 and retrieved from PubMed/MEDLINE. The search terms included “ Alzheimer's disease ”, “ therapy ”, “ monoclonal antibodies ” and “ novel ”. Result: From 108 articles, four studies were included. These studies indicate that mAbs represent a significant therapeutic advance in AD, focusing on two primary therapies: aducanumab and lecanemab. Both demonstrated efficacy in reducing beta‐amyloid plaques (Ramanan VK, et al, 2023; Day GS et al, 2022) and slowing cognitive and functional decline, particularly in patients at the early stages of AD, with reductions in the cognitive decline of 25% (Ramanan VK et al, 2023) and 30% (Cummings J et al, 2023). However, the clinical benefits of these therapies remain contentious due to serious adverse effects, notably amyloid‐related imaging abnormalities, reported in 21.3% (Ramanan VK et al, 2023) to 40% (Day GS et al, 2022) of patients. Additionally, donanemab has shown the ability to remove up to 86% of cerebral amyloid; however, concerns about its safety and the statistical validity of its results (Hoilund‐Carlsen PF et al, 2023) have been raised. All treatments necessitate a robust diagnostic and monitoring infrastructure and entail high costs, which limits accessibility. Conclusion: Our analysis of studies on mAb therapy for AD concluded that these new therapies significantly impact the reduction of amyloid plaques and the slowing of cognitive decline in the early stages of the disease. Nevertheless, these alternative interventions present new risks and still need to prove their clinical applicability in more robust studies, particularly regarding safety, infrastructure, and costs. Therefore, further research should aim to address these challenges in the fight against AD using mAbs.

14 October 2026 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
ARAndré Luiz Schuh Teixeira da Rosa
André Luiz Schuh Teixeira da Rosa
LCLucas de Oliveira Cia
Lucas de Oliveira Cia
GSGabriela Bezerra Sorato
Gabriela Bezerra Sorato
FMFelipe de Moura Manjabosco
Felipe de Moura Manjabosco
OBOlivia Sorato Bezerra
Olivia Sorato Bezerra
AGAna Soledade Graeff-Martins
Ana Soledade Graeff-Martins
Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet in children and adolescents it remains off-label and underused, constrained by safety concerns and scarce pediatric-specific evidence. Its benefits may extend beyond any single diagnostic category to severe, treatment-resistant dimensions of psychopathology that recur across diagnoses. This review traces clozapine’s history in youth, synthesizes the current evidence, and organizes it by domains of treatment resistance: psychosis, aggression, affective symptoms, suicidality and self-directed harm, and catatonia, with sections on real-world outcomes, clinical management, and safety. Randomized controlled data are confined to treatment-resistant early-onset schizophrenia and to one small trial in conduct disorder, with the first prospective open-label trial now available in autistic youth. Elsewhere the evidence is observational and of lower certainty, although convergent for aggression, suicidality, mood, and catatonia. The strongest transdiagnostic evidence is register-based and within-individual, drawn from cohorts aged 16 years and older, and spans psychotic and affective disorders; the pediatric gap concerns study design as well as sample size. Because pharmacovigilance data show that mortality is not concentrated in the hematological domain, safe use requires surveillance beyond blood counts, therapeutic drug monitoring, and safeguards over drug supply when suicide risk is present. Viewing clozapine as a treatment option defined by symptom severity and refractoriness may support rational use in severely ill youth, but the proposal remains preliminary: a conceptual framework that requires prospective, dimensionally designed pediatric studies. Clozapine’s potential transdiagnostic anti-suicidal effect merits priority investigation, given that suicide is a leading cause of death in adolescence.